Oculis CEO Riad Sherif MD to Participate in Glaucoma 360 New Horizons Forum

Oculis CEO Riad Sherif MD to Participate in Glaucoma 360 New Horizons Forum


LAUSANNE, Switzerland, January 31st, 2023 – Oculis S.A., (‘Oculis’) a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that its Chief Executive Officer, Riad Sherif, M.D., will be participating in the Glaucoma 360 New Horizons Forum in San Francisco, California, on Friday February 3, as a panelist in The Future in Vision Restoration and Neuroprotection session.

Time: 10:45-11:55 PST / 19:45-20:55 CET


Wiley Chambers, M.D., Director, Division of Ophthalmology, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration (FDA)

Nancy J. Newman, M.D., LeoDelle Jolley Chair in Ophthalmology, Professor of Ophthalmology and Neurology and Instructor in Neurological Surgery, Emory University School of Medicine; Director of Neuro-Ophthalmology, Emory Eye Center

José-Alain Sahel, M.D., Distinguished Professor and Chairman, Department of Ophthalmology, University of Pittsburgh School of Medicine

Riad Sherif, M.D., Oculis CEO


Kimberly Gokoffski, M.D., PhD, Assistant Professor, Clinical Ophthalmology and Associate Director of Research, Institute for Technology and Medical Systems, Keck School of Medicine, University of Southern California

Jeffrey Goldberg, M.D., PhD, Professor and Chair of Ophthalmology, Byers Eye Institute, Stanford University


Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industry, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment. Presented by the Glaucoma Research Foundation, this annual catalyst meeting is designed to bring the essential components together in order to speed the translation of new ideas into clinical practice. The event is part of Glaucoma 360, the annual three-day event uniting research, industry and philanthropy to prevent vision loss from glaucoma and speed the cure.

Oculis’s product candidate OCS-05 is a novel serum/glucocorticoid-regulated protein kinase 2 (“SGK2”) activator peptidomimetic small molecule. It is currently in development as a potential disease modifying neuroprotective agent against neurological damage to the optic nerve. Oculis is initially developing OCS-05 as a potential therapeutic to treat acute optic neuritis (AON), a rare disease with high unmet need as currently, there is no treatment which is approved by the FDA. OCS-05 has been granted Orphan Drug Designation by both the FDA and the EU for this indication. Preclinical studies with OCS-05 suggest neuroprotective and remyelinating activity, while in a European Phase 1 clinical trial in healthy volunteers, OCS-05 was observed to be well tolerated. Oculis is currently conducting a First-in-Patient clinical trial in France to evaluate the candidate’s safety and tolerability in patients with AON, and plans to conduct IND-enabling activities for OCS-05 in the United States.



About Oculis

Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’s highly differentiated pipeline consists of innovative product candidates in development including OCS-01, a topical retinal candidate for diabetic macular edema (DME),  OCS-02, a topical biologic candidate for dry eye disease (DED) and OCS-05, a disease modifying candidate for neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the U.S. and China, Oculis’s goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculis.com




Oculis / Investor Relations

Dr. Riad Sherif, CEO

Sylvia Cheung, CFO

Louie-Anne Gauthier, VP Strategic Marketing, BD&L and Corporate Communications


Media Relations

Consilium Strategic Communications
Amber Fennell, Matthew Cole, David Daley